Reading INVA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track INVA free→Reading INVA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track INVA free→NASDAQHealth CareBiotechnologySnapshot 2026-06-15
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is strong, but earnings quality is fragile, reported profits aren't backed by cash. Management's recent track record has been steady, and it has a capital-friendly stance. Risk is moderate, while the sector backdrop is a headwind, suggesting challenges ahead. Peer multiples imply a price about 50% above where it trades (it looks cheap on this basis); the read is cheap, value-trap risk, as it trades below peer multiples, but recent financials are weak or earnings quality is fragile. If INVA cuts guidance on the next call, that's a meaningful negative. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 6 valuation methods, at three horizons. Current price $22.42. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $22 INVA trades at 6× p/e, below its 13× p/e peer median. Our $45 fair value sits above the price; low confidence. Analysts: $32–$42. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price implies about 50% below a flat-multiple fair value, below our forecast of about 57%. This describes what's priced in, not a forecast of the move.
Only weak execution quality, a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 59% of the time over the next year (vs 52% for the rest of the cohort, n=2344).
Over the trailing year it converted 0.36x of net income into operating cash flow. Historically, Health Care names rated fragile grew net income 40% of the time over the next year (vs 56% for the rest of the cohort, n=1703).
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, long-term interest rates, real (inflation-adjusted) rates, Fed net liquidity.
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $0.50 → $0.50 (+0.0% / 30d). 1 raised, 1 cut, 1 covering analysts.
0 upgrades, 0 downgrades / 30d, 2 maintained. 75% of analysts rate Buy.
0 positive, 0 negative / 30d.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$109.
How much price usually moves either way.
On a bad day, this stock has moved -$246.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $2,353.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-15
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Improving net income shows the company is managing costs well. This supports growth goals.
Confirms:Q2 net income shows a year-over-year increase.
Disproves:Q2 net income shows a year-over-year decline.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for INVA yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b) On May 12, 2026, Derek Small and Mark DiPaolo Esq. tendered their resignations from the Board of Directors of Innoviva, Inc. (the “Board” and the “Company”), in order to focus on the growth of Syndeio BioSciences Inc. (“Syndeio”), where Mr. Small serves as Chief Executive Officer and Mr. DiPaolo is expected to assume an executive position. The…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
$32.00 – $42.00 (median $35.00) · 3 analysts · as of 2026-05-07
Looks cheaper than most peers in the same business.
Around its own typical valuation.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Pharmaceuticals.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
INVA Innoviva, Inc. | Above typical Show detailsSector percentile: 78 of 100 | inexpensive | moderate |
LLY Lilly (Eli) | Above typical Show detailsSector percentile: 88 of 100 | expensive | moderate |
JNJ Johnson & Johnson | Above typical Show detailsSector percentile: 74 of 100 | expensive | low |
MRK Merck & Co. | Typical Show detailsSector percentile: 67 of 100 | expensive | moderate |
PFE Pfizer | Typical Show detailsSector percentile: 61 of 100 | fair | low |
1 material management or governance event in the past 24 months, led by executive changes. Historically, Health Care names rated stable grew net income 56% of the time over the next year (vs 52% for the rest of the cohort, n=618).
Not investment advice. As of 2026-06-15.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-15.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Management is prioritizing revenue growth as a key strategic focus.
Management aims to enhance net income through operational improvements.
Management is focused on improving operating income through efficiency gains.
Why it matters: Better operating income shows that management is controlling costs. This is important for making more money long-term.
Confirms:Operating income increases from $38.2M in Q1 to above $40M in Q2.
Disproves:Operating income decreases or stays below $38M in Q2.
Why it matters: Leadership changes can affect how the company runs. It matters to see how the new leaders change Innoviva's path.
Confirms one read:Good news about new plans or actions from the new board members.
Confirms the other:Negative news or lack of direction from the new board members.
Why it matters: A drop below 10% signals that revenue growth is slowing. This could impact investor confidence.
Confirms:Q2 revenue growth reported below 10% year over year.
Disproves:Q2 revenue growth reported at or above 10% year over year.
Why it matters: Meeting this sales target would show strong growth for Innoviva's IST platform. It proves the company can use its recent FDA approvals well.
Confirms:U.S. net product sales of IST reported above $150 million for 2026.
Disproves:U.S. net product sales of IST reported below $120 million for 2026.
Why it matters: More share buybacks would show management's trust in the company's value and future.
Confirms:More shares bought back under the $125 million program.
Disproves:No more share buybacks announced under the program.
Why it matters: More share buybacks show that management trusts the company's value and finances.
Confirms:Innoviva plans to increase share buybacks beyond the current $125 million program.
Disproves:No new announcements on share repurchases or a slowdown in the current program.
Why it matters: Some directors have recently resigned. This may change the company's plans and stability.
Confirms:New directors are appointed quickly to fill the vacancies.
Disproves:If no new leaders are chosen, uncertainty will continue.
Why it matters: A clear plan for NUZOLVENCE would show Innoviva is ready to launch its new product.
Confirms:A detailed plan for NUZOLVENCE's launch will be announced for the second half of 2026.
Disproves:Delay in the commercialization plan or lack of a partner for NUZOLVENCE.
of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.